SteelPeak Wealth LLC Boosts Amgen Inc. Holdings by 28%

Institutional investor now owns over $37 million in Amgen shares

Apr. 4, 2026 at 10:13am

Got story updates? Submit your updates here. ›

SteelPeak Wealth LLC, an institutional investor, increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 28.1% in the fourth quarter, according to a recent SEC filing. The firm now owns 115,728 shares of the medical research company's stock, valued at $37.88 million.

Why it matters

This investment signals SteelPeak Wealth's confidence in Amgen's long-term growth potential as a leading biopharmaceutical company. Amgen's diverse portfolio of approved drugs and robust pipeline of investigational therapies make it an attractive investment for institutional investors seeking exposure to the biotech sector.

The details

SteelPeak Wealth LLC's increased stake in Amgen represents 1.2% of the firm's total investment portfolio. Amgen is now the 20th largest holding for SteelPeak Wealth. The institutional investor purchased an additional 25,389 shares of Amgen during the fourth quarter.

  • SteelPeak Wealth LLC filed its latest 13F report with the SEC on April 4, 2026, disclosing its Q4 2025 holdings.
  • The firm increased its Amgen position during the fourth quarter of 2025.

The players

SteelPeak Wealth LLC

An institutional investment firm that manages a diversified portfolio of stocks, bonds, and other assets on behalf of its clients.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

SteelPeak Wealth's increased investment in Amgen highlights the company's appeal as a leading biotech firm with a strong product portfolio and promising pipeline. This move reflects the institutional investor's confidence in Amgen's long-term growth potential within the rapidly evolving pharmaceutical industry.